Korlym mifepristone: Phase I data

Researchers at the University of Chicago and colleagues reported data from a double-blind, placebo-controlled, U.S. Phase I trial in patients with advanced breast cancer showing that mifepristone plus Abraxane nab-paclitaxel led to a complete or partial response in 5 of 8 evaluable patients with relapsed, metastatic triple-negative breast cancer (TNBC). The combination was well tolerated. Data were presented at the San Antonio Breast Cancer Symposium. This quarter, Corcept plans to start an open-label Phase I trial evaluating mifepristone plus Halaven eribulin meyslate in up to 40 patients with metastatic TNBC. ...